Percheron Therapeutics Limited has released a press release.
ATL1102 for Multiple Sclerosis - Progress Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Percheron Therapeutics Limited on 6ix
Story so far
Earlier from Percheron Therapeutics
- Capital Management Initiatives - Update
- ATL1103 Higher Dose Study
- Company Update
- Positive Results Achieved from ATL1103 Higher Dose Study
- ATL1103 Granted Orphan Drug Designation in Europe
Later from Percheron Therapeutics
- Bonus and New Options Offer Prospectus
- Appendix 3C
- ATL1102 for MS - Progress Update
- ATL1103 Patent Update
- Market and Technology Update
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics